6598 Erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC): preliminary results from a multicenter phase II study

✍ Scribed by Milella, M.; Sperduti, I.; Gelibter, A.; Bria, E.; Cianci, G.; Moscetti, L.; Mansueto, G.; Ruggeri, E.M.; Gamucci, T.; Cognetti, F.

• Book ID: 122845125
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 48 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(09)71319-9